These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. A folate receptor-α-specific ligand that targets cancer tissue and not sites of inflammation. Vaitilingam B; Chelvam V; Kularatne SA; Poh S; Ayala-Lopez W; Low PS J Nucl Med; 2012 Jul; 53(7):1127-34. PubMed ID: 22693311 [TBL] [Abstract][Full Text] [Related]
24. Development of new folate-based PET radiotracers: preclinical evaluation of ⁶⁸Ga-DOTA-folate conjugates. Fani M; Wang X; Nicolas G; Medina C; Raynal I; Port M; Maecke HR Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):108-19. PubMed ID: 20799032 [TBL] [Abstract][Full Text] [Related]
25. Advancements in folate receptor targeting for anti-cancer therapy: A small molecule-drug conjugate approach. Rana A; Bhatnagar S Bioorg Chem; 2021 Jul; 112():104946. PubMed ID: 33989916 [TBL] [Abstract][Full Text] [Related]
26. Clinical translation of folate receptor-targeted therapeutics. Teng L; Xie J; Teng L; Lee RJ Expert Opin Drug Deliv; 2012 Aug; 9(8):901-8. PubMed ID: 22663189 [TBL] [Abstract][Full Text] [Related]
29. Advances in non-radioactive PSMA-targeted small molecule-drug conjugates in the treatment of prostate cancer. Chen M; Cai L; Xiang Y; Zhong L; Shi J Bioorg Chem; 2023 Dec; 141():106889. PubMed ID: 37813074 [TBL] [Abstract][Full Text] [Related]
30. Folate-vinca alkaloid conjugates for cancer therapy: a structure-activity relationship. Leamon CP; Vlahov IR; Reddy JA; Vetzel M; Santhapuram HK; You F; Bloomfield A; Dorton R; Nelson M; Kleindl P; Vaughn JF; Westrick E Bioconjug Chem; 2014 Mar; 25(3):560-8. PubMed ID: 24564229 [TBL] [Abstract][Full Text] [Related]
31. Folate-targeted enzyme prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug. Lu JY; Lowe DA; Kennedy MD; Low PS J Drug Target; 1999; 7(1):43-53. PubMed ID: 10614814 [TBL] [Abstract][Full Text] [Related]
32. Folate receptor-targeted fluorescent paramagnetic bimodal liposomes for tumor imaging. Ding N; Lu Y; Lee RJ; Yang C; Huang L; Liu J; Xiang G Int J Nanomedicine; 2011; 6():2513-20. PubMed ID: 22072885 [TBL] [Abstract][Full Text] [Related]
33. Folate-mediated targeting of therapeutic and imaging agents to cancers. Reddy JA; Low PS Crit Rev Ther Drug Carrier Syst; 1998; 15(6):587-627. PubMed ID: 9883391 [TBL] [Abstract][Full Text] [Related]
34. Augmented cytotoxic effects of paclitaxel by curcumin induced overexpression of folate receptor-α for enhanced targeted drug delivery in HeLa cells. Dhanasekaran S Phytomedicine; 2019 Mar; 56():279-285. PubMed ID: 30668349 [TBL] [Abstract][Full Text] [Related]
35. Gefitinib loaded folate decorated bovine serum albumin conjugated carboxymethyl-beta-cyclodextrin nanoparticles enhance drug delivery and attenuate autophagy in folate receptor-positive cancer cells. Shi Y; Su C; Cui W; Li H; Liu L; Feng B; Liu M; Su R; Zhao L J Nanobiotechnology; 2014 Oct; 12():43. PubMed ID: 25358257 [TBL] [Abstract][Full Text] [Related]
36. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models. Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718 [TBL] [Abstract][Full Text] [Related]
37. Folate receptor expression on murine and human adipose tissue macrophages. Hansen MJ; Achini Bandara N; Low PS Inflamm Res; 2015 Sep; 64(9):697-706. PubMed ID: 26149693 [TBL] [Abstract][Full Text] [Related]
39. Characterization of in vivo disulfide-reduction mediated drug release in mouse kidneys. Yang JJ; Kularatne SA; Chen X; Low PS; Wang E Mol Pharm; 2012 Feb; 9(2):310-7. PubMed ID: 22171616 [TBL] [Abstract][Full Text] [Related]